Nothing Special   »   [go: up one dir, main page]

BR0210189A - Dnazimas de bcl-2 - Google Patents

Dnazimas de bcl-2

Info

Publication number
BR0210189A
BR0210189A BR0210189-0A BR0210189A BR0210189A BR 0210189 A BR0210189 A BR 0210189A BR 0210189 A BR0210189 A BR 0210189A BR 0210189 A BR0210189 A BR 0210189A
Authority
BR
Brazil
Prior art keywords
bcl
domain
catalytic domain
mrna
nucleotides
Prior art date
Application number
BR0210189-0A
Other languages
English (en)
Inventor
Lun-Quan Sun
Li Wang
Rachel Jane Turner
Edward George Saravolac
Crispin Rajnish Dass
Original Assignee
Johnson & Johnson Res Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson & Johnson Res Pty Ltd filed Critical Johnson & Johnson Res Pty Ltd
Publication of BR0210189A publication Critical patent/BR0210189A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"DNAZIMAS DE BCL-2". A presente invenção fornece DNAzimas que clivam especificamente mRNA transcrito de um elemento da família do gene bc1-2 selecionado do grupo consistindo em bcl-2, bcl-x1, bcl-w, bf1-1, brag-1, Mcl-1 e A1. As DNAzimas compreendem (a) um domínio catalítico que possui a seq³ência de nucleotídeo GGCTAGCTACAACGA (SEQ ID NO. 1) e cliva mRNA em qualquer sítio de clivagem de purina: pirimidina para o qual ele é dirigido, (b) um domínio de ligação contínuo com a extremidade 5<39> do domínio catalítico e (c) outro domínio de ligação contínuo com a extremidade 3<39> do domínio catalítico. Os domínios de ligação são complementares e portanto, hibridizam com as duas regiões imediatamente flanqueando o resíduo de purina do sítio de clivagem dentro do mRNA da família do gene bcl-2 onde a clivagem catalisada da DNAzima é desejada. Cada domínio de ligação possui, pelo menos, seis nucleotídeos de comprimento e ambos domínios de ligação possuem um comprimento total combinado de pelo menos 14 nucleotídeos.
BR0210189-0A 2001-06-07 2002-06-07 Dnazimas de bcl-2 BR0210189A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPR5527A AUPR552701A0 (en) 2001-06-07 2001-06-07 Bcl-2 dnazymes
PCT/AU2002/000739 WO2002099090A1 (en) 2001-06-07 2002-06-07 Bcl-2 dnazymes

Publications (1)

Publication Number Publication Date
BR0210189A true BR0210189A (pt) 2004-08-03

Family

ID=3829501

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0210189-0A BR0210189A (pt) 2001-06-07 2002-06-07 Dnazimas de bcl-2

Country Status (10)

Country Link
US (1) US20050064407A1 (pt)
EP (1) EP1402007A1 (pt)
JP (1) JP2004532046A (pt)
KR (1) KR20040028771A (pt)
AU (1) AUPR552701A0 (pt)
BR (1) BR0210189A (pt)
CA (1) CA2449940A1 (pt)
IL (1) IL159197A0 (pt)
MX (1) MXPA03011153A (pt)
WO (1) WO2002099090A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7482158B2 (en) * 2004-07-01 2009-01-27 Mathison Brian H Composite polynucleic acid therapeutics
CN101914538A (zh) * 2010-08-03 2010-12-15 孙仑泉 一种促进肿瘤细胞凋亡的脱氧核酶
CN101940783A (zh) * 2010-08-03 2011-01-12 孙仑泉 脱氧核酶在制备增强肿瘤化疗敏感性的药物中的应用
CN106047874B (zh) * 2016-06-02 2019-01-18 吉林大学 一种靶向sall4基因的脱氧核酶分子及在乳腺癌基因治疗中的应用
WO2019171191A1 (en) * 2018-03-05 2019-09-12 Dr. Reddy's Institute Of Life Sciences Embryonic zebrafish models using dnazyme mediated knockdown
CN112410295B (zh) * 2020-11-20 2023-07-28 华东理工大学 一种控制细胞间相互作用的细胞表面工程方法及其应用
KR20230133859A (ko) 2020-12-28 2023-09-19 1이 테라퓨틱스 엘티디. p21 mRNA 표적화 DNA자임
EP4267741A2 (en) * 2020-12-28 2023-11-01 1E Therapeutics, Ltd. P21 mrna target areas for silencing
GB202107029D0 (en) * 2021-05-17 2021-06-30 Univ Of Essex Enterprises Limited DNAzyme design
WO2024119159A1 (en) * 2022-12-01 2024-06-06 The Regents Of The University Of California Functionally enhanced 10-23 dna enzyme with chemically optimized catalytic core

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001992A (en) * 1999-01-07 1999-12-14 Isis Pharmaceuticals Inc. Antisense modulation of novel anti-apoptotic bcl-2-related proteins
US5539094A (en) * 1993-11-12 1996-07-23 La Jolla Cancer Research Foundation DNA encoding Bcl-2-associated proteins
AUPN896596A0 (en) * 1996-03-27 1996-04-26 Walter And Eliza Hall Institute Of Medical Research, The Therapeutic molecules
US6214986B1 (en) * 1998-10-07 2001-04-10 Isis Pharmaceuticals, Inc. Antisense modulation of bcl-x expression

Also Published As

Publication number Publication date
US20050064407A1 (en) 2005-03-24
WO2002099090A1 (en) 2002-12-12
MXPA03011153A (es) 2004-03-26
IL159197A0 (en) 2004-06-01
AUPR552701A0 (en) 2001-07-12
JP2004532046A (ja) 2004-10-21
CA2449940A1 (en) 2002-12-12
KR20040028771A (ko) 2004-04-03
EP1402007A1 (en) 2004-03-31

Similar Documents

Publication Publication Date Title
Napierala et al. CUG repeats present in myotonin kinase RNA form metastable “slippery” hairpins
Peng Ho et al. Potent antisense oligonucleotides to the human multidrug resistance-1 mRNA are rationally selected by mapping RNA-accessible sites with oligonucleotide libraries
Zahler et al. Distinct functions of SR proteins in recruitment of U1 small nuclear ribonucleoprotein to alternative 5'splice sites.
Porta et al. An allosteric hammerhead ribozyme
Schmidt et al. Information transfer from peptide nucleic acids to RNA by template-directed syntheses
ES2447419T3 (es) Composiciones para la amplificación isotérmica lineal de secuencias de polinucleótidos
Santoro et al. A general purpose RNA-cleaving DNA enzyme
Licht et al. Telomerase RNA function in recombinant Tetrahymena telomerase
CY1122342T1 (el) Ειδικοι ως προς την ακολουθια rna μεσολαβητες της παρεμβολης rna
PT731835E (pt) Oligonucleotidos anti-sentido possuindo actividade inibidora de tumorigenicidade
Hamilton et al. Duplex strand joining reactions catalyzed by vaccinia virus DNA polymerase
WO1999014226A3 (en) Bi- and tri-cyclic nucleoside, nucleotide and oligonucleotide analogues
US7083926B2 (en) Method for identifying accessible binding sites on RNA
DE69934227D1 (de) Auf beta-arabinose, und dessen analogen, basierte antisense oligonukleotide
BR0210189A (pt) Dnazimas de bcl-2
IL98543A (en) Endonuclease and its use in the cleavage of a target nucleic acid sequence
ATE309345T1 (de) Antitumor antisense sequenzen gegen h1 und r2 verbindungen von ribonukleotide reductase
Nagel et al. Specific binding of an exonic splicing enhancer by the pre-mRNA splicing factor SRp55.
Patel et al. Formation of chimeric DNA primer extension products by template switching onto an annealed downstream oligonucleotide.
Milne et al. An approach to gene-specific transcription inhibition using oligonucleotides complementary to the template strand of the open complex
ATE293688T1 (de) Chimerische antisense-oligonukleotide aus arabinofuranose-analogen und deoxyribose- nukleotide
Nashimoto Anomalous RNA substrates for mammalian tRNA 3′ processing endoribonuclease
Pradeepkumar et al. Oxetane modified antisense oligonucleotides promote RNase H cleavage of the complementary RNA strand in the hybrid duplex as efficiently as the native, and offer improved endonuclease resistance
Peyman et al. Nuclease stability as dominant factor in the antiviral activity of oligonucleotides directed against HSV-1 IE110
Shen et al. Impact of mixed-backbone oligonucleotides on target binding affinity and target cleaving specificity and selectivity by Escherichia coli RNase H

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]